Logotype for Dogwood Therapeutics Inc

Dogwood Therapeutics (DWTX) Registration filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Dogwood Therapeutics Inc

Registration filing summary

30 Oct, 2026

Company overview and business model

  • Development-stage biopharma focused on medicines for cancer-treatment pain and peripheral neuropathy, with potential expansion into other pain conditions after clinical success.

  • Halneuron, a NaV 1.7 modulator, is in Phase 2b for chronic pain after cancer chemotherapy; it has FDA Fast Track designation and prior Phase 2 evidence of pain reduction with an acceptable safety profile.

  • SP16, a proprietary immunomodulatory and anti-inflammatory peptide, is poised to enter Phase 1 for chemotherapy-induced peripheral neuropathy; preclinical findings suggest potential neuroprotective effects.

Financial performance and metrics

  • Forvis Mazars’ audit report on FY2025 and FY2024 consolidated financial statements contains an explanatory paragraph citing substantial doubt about the ability to continue as a going concern.

Use of proceeds and capital allocation

  • The October 19, 2026 private placement generated approximately $5.0 million gross proceeds at $1.22 per share; proceeds are intended for general working capital.

  • No proceeds will be received from Sealbond’s resales under this prospectus; the selling stockholder receives resale proceeds and pays its brokerage fees, commissions and similar selling expenses.

  • Registration fees and expenses are payable by the issuer; estimated registration costs total $53,897.56, including legal, audit and transfer-agent expenses.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dogwood Therapeutics